Skip to main content

Table 3 Clinicopathologic characteristics according to residual tumor after surgery

From: Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study

Characteristics No gross residual
(n = 23, %)
Any residual tumor
(n = 9, %)
P-value
Age at diagnosis, years    0.360
  Median (range) 56 (34–77) 52 (43–70)  
Menopausal status    0.682
  Premenopause 6 (26.1) 3 (33.3)  
  Postmenopause 17 (73.9) 6 (66.7)  
 Histologic subtype    0.798
  Endometrioid 12 (52.2) 6 (66.7)  
  Serous 4 (17.4) 1 (11.1)  
  Clear cell 1 (4.3) 0  
  Carcinosarcoma 4 (17.4) 2 (22.2)  
  Others 2 (8.7) 0  
Grade    0.712
  Low 7 (30.4) 4 (44.4)  
  High 5 (21.8) 2 (22.2)  
  Not applicable 11 (47.8) 3 (33.3)  
FIGO stage    0.181
  IIIC 4 (17.4) 0  
  IVB 19 (82.6) 9 (100)  
CA-125 at diagnosis, IU/ml    0.417
  Median (range) 144 (8.6–3489.0) 474 (24.7–3440.0)  
CA-125 after NAC, IU/ml    0.417
  Median (range) 18.6 (7.0–391.0) 43.1 (15.0–1490.0)  
NAC regimen    0.477
  Paclitaxel-carboplatin 16 (69.6) 9 (100)  
  Doxorubicin-cisplatin 2 (8.7) 0  
  Paclitaxel-cisplatin-bevacizumab 2 (8.7) 0  
  Ifosfamide-cisplatin 2 (8.7) 0  
  Etoposide-cisplatin 1 (4.3) 0  
Number of NAC cycles    0.296
  Median (range) 6 (2–12) 4 (2–9)  
  2–3 8 (34.8) 3 (33.3)  
  4–6 5 (21.7) 5 (55.6)  
  ≥7 10 (43.5) 1 (11.1)  
Response to NAC    0.008
  CR 2 (8.7) 0  
  PR 20 (87.0) 4 (44.4)  
  SD 1 (4.3) 3 (33.3)  
  PD 0 2 (22.2)  
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, NAC Neoadjuvant chemotherapy, IDS Interval debulking surgery, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease